Health Innovation Manchester (HInM) has published its Impact Report for 2022-2023.
The report details how HInM has delivered against all its key commissions from NHS England and the Office of Life Sciences through 2022/23.
Key highlights in the report include:
- Strong delivery against all national AHSN requirements across its various commissions including delivery to the requirements of NHS England and Office of Life Sciences commissions.
- Success in the Manchester Biomedical Research Centre bid, which has been awarded £59.1m over five years, a significant uplift on the previous settlement.
- Successfully securing a grant from Innovate UK and industry investment for a circa £20m innovation accelerator programme.
- Leading on the design and development of a GM approach for virtual wards, which is now currently delivering >400 virtual beds across the system.
- Grown the use of GM Care Record by around 25% in year to 19,000 users and 190,000 patient consultations per month, and driven academic outputs from the GM Care Record (3 publications, 42 studies in the pipeline overall).
- Led the successful wave 1 NHS England Secure Data Environment bid process for GM and the wider NW region, securing £11m over three years.
- Led on successful bids through 2022/23 to leverage over £100m of investment into the GM system.
The need for fast-paced innovation in healthcare is widely acknowledged. And ensuring that healthcare innovation is shaped by the people it serves remains a pressing priority – one made all the more evident by the growing emphasis on health equity in the 10 Year Health Plan. Patient voices are often cited as central to healthcare [...]
The NHS Innovation Accelerator (NIA) has revealed its 2025 cohort of Fellows. As the NIA celebrates a decade of helping to drive innovation in the NHS, this year’s cohort aligns with the Government’s three priorities: supporting the transition from analogue to digital, sickness to prevention and hospital to home. The 28 new Fellows will benefit [...]
A new guide aimed at helping primary care organisations and integrated care boards understand and address problematic polypharmacy has been launched by the Health Innovation Network as part of its national Polypharmacy Programme. Developed in response to a clear need identified by primary care and prescribing colleagues, this essential resource provides practical, evidence-based strategies to [...]
